Erythematotelangiectatic Rosacea Clinical Trial
Official title:
Pilot Study to Evaluate Vbeam® Prima Pulsed Dye Laser (PDL) Treatment and RHOFADE® (Oxymetazoline HCL, 1% Cream) for Erythematotelangiectatic Rosacea
Verified date | March 2022 |
Source | Candela Corporation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will compare treatment outcome with pulsed dye laser, when used used as an adjunctive treatment to oxymetazoline HCl 1% cream, compared to oxymetazoline HCL 1% cream alone, for patients with moderate or severe erythematotelangiectatic rosacea.
Status | Completed |
Enrollment | 34 |
Est. completion date | January 5, 2021 |
Est. primary completion date | November 13, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Subject is a healthy male or female of 18 to 75 years of age. 2. Subject has erythematotelangiectatic rosacea with clinician erythema assessment (CEA) and subject self-assessment (SSA) of "moderate" or "severe" (Grade 3 or 4). 3. Fitzpatrick Skin Type I - VI. 4. Subject must be able to read, understand and sign the Informed Consent Form. 5. Subject must be willing and able to adhere to the treatment and follow-up schedule and post-treatment care instructions. 6. Subject must be willing to have limited sun exposure for the duration of the study, including the follow-up period up to 6 months post-baseline. 7. Subject is willing to have photographs taken of the treated area that will be used, de-identified, in evaluations and may be used, de-identified, in presentations and/or publications. 8. For female candidates - subject must be post-menopausal, or surgically sterilized, or using a medically acceptable form of birth control during the entire course of the study. Exclusion Criteria: 1. Subject is pregnant or planning to become pregnant during the study duration. 2. Subject has an active electrical implant anywhere in the body, such as a pacemaker or an internal defibrillator. 3. Subject has an implant in the treated area (such as metal plates or screws) or an injected chemical substance. 4. Subject has a known collagen (connective tissue) disorder, vascular disease, scleroderma or other autoimmune disease (i.e. rheumatoid arthritis, lupus). 5. Subject has a history of diseases stimulated by heat or sun exposure, such as recurrent Herpes Simplex in the treated area, unless treatment is conducted following a prophylactic regimen. 6. Subject has a history of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications. 7. Having or undergoing any form of treatment for active cancer or having a history of skin cancer or any other cancer in the areas to be treated, including presence of malignant or pre-malignant pigmented lesions. 8. Subject is suffering from significant concurrent illness, such as such as cardiac disorders, diabetes (type I or II), or pertinent neurological disorders. 9. Subject has an infection or is suffering from current or has a history of significant skin conditions in the treated area or inflammatory skin conditions, including, but not limited to: photodermatoses, active acne, excessive skin dryness, psoriasis, eczema, rash, open wounds, varicella scars, open lacerations or abrasions and active cold sores or herpes sores prior to treatment (duration of resolution as per the Investigator's discretion) or during the treatment course. 10. Having a known anticoagulative or thromboembolic condition or taking anticoagulation medications one week prior to and during the treatment course (to allow inclusion, temporary cessation of use might be requested as per the subject's physician discretion). 11. Use of non-steroidal anti-inflammatory drugs (NSAIDS, e.g., ibuprofen-containing agents) one week before and after each treatment session. 12. Subject has a history of pigmentary disorders, particularly tendency for hyper- or hypo-pigmentation. 13. Subject has a history of keloid scarring or of abnormal wound healing. 14. Subject has a known photosensitivity to the device's laser wavelengths, history of ingesting medications known to induce photosensitivity, or history of seizure disorders due to light. 15. Subject has undergone any surgical, light-based therapy or radiofrequency (RF) procedures in the treatment area within 3 months of treatment or during the study. 16. Having undergone any other surgery in the treated area within 3 months of treatment (or more if skin has not healed completely) or during the study. 17. Subject has a tattoo or permanent make-up in the treated area. 18. Subject has systemically used retinoids or antioxidants within 1 month of treatment or during the study. 19. Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning during the study. 20. Participation in a study of another device or drug within three months prior to enrollment or during the study. 21. As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study. |
Country | Name | City | State |
---|---|---|---|
United States | Dermatology, Laser & Vein Specialists of the Carolinas | Charlotte | North Carolina |
United States | Dermatology & Laser Surgery Center | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
Candela Corporation |
United States,
Bernstein EF, Schomacker K, Paranjape A, Jones CJ. Pulsed dye laser treatment of rosacea using a novel 15 mm diameter treatment beam. Lasers Surg Med. 2018 Oct;50(8):808-812. doi: 10.1002/lsm.22819. Epub 2018 Apr 10. — View Citation
DuBois J, Dover JS, Jones TM, Weiss RA, Berk DR, Ahluwalia G. Phase 2 Randomized, Dose-Ranging Study of Oxymetazoline Cream for Treatment of Persistent Facial Erythema Associated With Rosacea. J Drugs Dermatol. 2018 Mar 1;17(3):308-316. — View Citation
Sodha P, Suggs A, Munavalli GS, Friedman PM. A Randomized Controlled Pilot Study: Combined 595-nm Pulsed Dye Laser Treatment and Oxymetazoline Hydrochloride Topical Cream Superior to Oxymetazoline Hydrochloride Cream for Erythematotelangiectatic Rosacea. — View Citation
Suggs AK, Macri A, Richmond H, Munavalli G, Friedman PM. Treatment of Erythematotelangiectatic Rosacea With Pulsed-Dye Laser and Oxymetazoline 1.0% Cream: A Retrospective Study. Lasers Surg Med. 2020 Jan;52(1):38-43. doi: 10.1002/lsm.23176. Epub 2019 Nov 10. — View Citation
Tan J, Liu H, Leyden JJ, Leoni MJ. Reliability of Clinician Erythema Assessment grading scale. J Am Acad Dermatol. 2014 Oct;71(4):760-3. doi: 10.1016/j.jaad.2014.05.044. Epub 2014 Jul 4. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Clinical Erythema Assessment (CEA) Score At 6-Month Post-Baseline | CEA was graded by the investigator according to 5-point scale (0=Clear to 4=Severe) for each patient at the 6-month post-baseline visits. A higher score indicates worse outcome. The outcomes presented here are the mean CEA calculated for the 6-month post-baseline visit of each arm. | 6-month post-baseline | |
Secondary | Clinical Erythema Assessment (CEA) At the 1- ,2- and 3-Month Post-Baseline Visits | Clinical Erythema Assessment (CEA) scores at the 1- ,2- and 3-month post-baseline visits were assessed for each patient by the investigator. CEA scores were graded according to 5-point scale (0=Clear to 4=Severe). A higher score indicates worse outcome. The outcomes presented here are the mean CEA calculated for each visit. | 1- ,2- and 3-Month Post-Baseline Visits | |
Secondary | Subject Self-Assessment (SSA) At the 1- ,2-, 3- and 6-Month Post-Baseline Visits | Subject Self-Assessment (SSA) at the 1- ,2-, 3- and 6-month post-baseline visits were graded according to 5-point scale (0=Clear of unwanted redness to 4=Completely unacceptable redness) at each visit. A higher score indicates worse outcome. | 1-, 2-, 3- and 6-months post-baseline | |
Secondary | Mean Investigator Assessment of Global Aesthetic Improvement (GAI) Grades At the 1-, 2-, 3- and 6-Month Post-Baseline | Investigator measurement of Global Aesthetic Improvement (GAI) with treatment. GAI is graded according to 5-point scale (0=Excellent improvement to 4=No change). A higher score indicates a worse outcome. The outcomes presented here are the mean GAI calculated for each visit. | 1-, 2-, 3- and 6-month post-baseline | |
Secondary | Mean Subject Assessment of Global Aesthetic Improvement (GAI) Grades At the 1-, 2-, 3- and 6-Month Post-Baseline | Subject measurement of Global Aesthetic Improvement (GAI) with treatment. GAI is graded according to 5-point scale (0=Excellent improvement to 4=No change). A higher score indicates a worse outcome. The outcomes presented here are the mean GAI calculated for each visit. | 1-, 2-, 3- and 6-month post-baseline | |
Secondary | Measurement of Improvement in Vessel Size At the 1-, 2-, 3- and 6-Month Post-Baseline Visits | Investigator assessment of improvement in vessel size with treatment. Improvement in vessel size is graded according to 4-point scale (0=76-100% improvement (excellent) to 4=No response). A higher score indicates a worse outcome. Mean score was calculated for each visit. | 1-, 2-, 3- and 6-month post-baseline | |
Secondary | Measurement of The Percentage of Subjects Reporting Satisfaction At the 6-Month Post-Baseline Visit | Subject satisfaction is graded according to 5-point scale (0=Very Satisfied to 4=Very Dissatisfied). Lower score indicates higher satisfaction. A score of 0 or 1 indicates satisfaction with treatment outcome. The measurements reflect the percentage of subjects that were satisfied (graded 0 or 1) at the 6-month post-baseline visit | 6-month post-baseline | |
Secondary | Measurement of Pain Associated With PDL Treatment | A standard 10-centimeter visual analog scale from 0=No pain to 10=worst pain was used by subjects to report pain level associated with PDL treatment. A higher score indicates greater pain/discomfort with treatment. Mean of all pain associated scores obtained for all PDL treatments was calculated. | 1-, 2- and 3-month post-baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03708263 -
Evaluation of the New Laser PHOTOLASE PLV-585nm for the Treatment of Rosacea
|
N/A | |
Completed |
NCT02268474 -
Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea
|
N/A | |
Completed |
NCT00989014 -
Dose-Finding Study of CD07805/47 Topical Gel in Subjects With Erythematotelangiectatic Rosacea
|
Phase 2 | |
Completed |
NCT01756027 -
Feasibility Study: Ulthera System for the Treatment of Rosacea
|
N/A | |
Completed |
NCT06331533 -
Intradermal BoNT-A Treatment in Erythematotelangiectatic Rosacea
|
Phase 4 | |
Completed |
NCT02144181 -
Ultherapy® for the Treatment of Erythematotelangiectatic Rosacea
|
N/A | |
Recruiting |
NCT05360251 -
Pulsed Dye Laser and Intense Pulsed Light Configured With Different Wavelength Bands in Improving Erythematotelangiectatic Rosacea
|
N/A | |
Completed |
NCT01045551 -
Open Label Pilot Study of Apremilast in Treatment of Rosacea
|
Phase 2 | |
Completed |
NCT00945373 -
Combination Therapy for the Treatment of Rosacea
|
Phase 1 | |
Completed |
NCT02393937 -
A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea
|
Phase 3 | |
Completed |
NCT02052999 -
Study to Evaluate the Efficacy and Safety of PAC-14028 Cream in Rosacea Patients
|
Phase 2 |